1. Introduction {#sec1-jcm-09-00326}
===============

Cancer is a disease caused by an uncontrolled division of abnormal cells in a part of the body due to breakdown in the processes which control cell proliferation, differentiation, and death of particular cells. According to the recent incidence and mortality data, there were an estimated 14.1 million new cancer cases and 8.2 million cancer deaths worldwide in 2012 \[[@B1-jcm-09-00326]\]. Recently, the relative survival of patients with cancer has gradually increased over time \[[@B2-jcm-09-00326]\] and the new anti-cancer regimens have broadened the therapeutic options for many cancer patients significantly. Nevertheless, cancer mortality is still high in most cancer types.

β-Hydroxy β-methylglutaryl-CoA (HMG-CoA), also known as 3-hydroxy-3-methylglutaryl-CoA, is an intermediate in the mevalonate and ketogenesis pathways, and its inhibitors (statins) have been used to reduce plasma cholesterol levels for preventing coronary heart disease \[[@B3-jcm-09-00326]\]. Although there have been earlier concerns on the carcinogenicity of statins, such as initiation or promotion of cancers in rodents at concentrations equivalent to those commonly prescribed in humans \[[@B4-jcm-09-00326]\], there has also been growing evidence which suggests that statins could have a chemopreventive effect against cancer \[[@B5-jcm-09-00326],[@B6-jcm-09-00326]\]

Although the potential mechanisms of the anti-cancer effect of statin are still elusive, inhibition of cancer cell growth, promotion of apoptotic cell death and inhibition of matrix metalloproteinases are involved in processes such as tumor growth, invasion, and metastasis have been suggested \[[@B7-jcm-09-00326],[@B8-jcm-09-00326],[@B9-jcm-09-00326]\].

Recently, there have been many epidemiologic studies and meta-analyses on the beneficial effect of statin on cancer incidence and mortality or survival. However, the results were conflicting on these associations \[[@B10-jcm-09-00326],[@B11-jcm-09-00326],[@B12-jcm-09-00326]\]. In addition, some of these reported associations could be caused by biases. We have previously examined the association between statin use and cancer incidence by performing an umbrella review by assessing the level of evidence \[[@B13-jcm-09-00326]\], but there has been no study focusing on cancer mortality. Therefore, to provide an overview of the strength of evidence, the extent of potential biases and the validity of the claimed associations between statin use and cancer mortality or survival, we performed an umbrella review of the evidence across the published meta-analyses on the associations between statin use and various kinds of cancer mortalities or survivals.

2. Methods {#sec2-jcm-09-00326}
==========

We performed an umbrella review of meta-analyses and systematic reviews on the associations between statin use and cancer mortality or survival. This umbrella review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@B14-jcm-09-00326]\]. The PRISMA checklist is shown in [Supplementary Materials](#app1-jcm-09-00326){ref-type="app"}.

2.1. Methods for Literature Search {#sec2dot1-jcm-09-00326}
----------------------------------

Two investigators (G.H.J. and J.I.S) searched the data and any discrepancies were resolved by discussion and consensus. We searched the literature using the PubMed database and selected the articles written in English. The last search was performed in August 2018. The following keywords were used to find the relevant articles: '(hydroxymethyl glutaryl-CoA reductase inhibitor OR statin) AND (cancer OR neoplasm OR tumor OR malignancy) AND (meta-analysis OR systematic review) AND (survival OR mortality OR death)'. We carefully reviewed the retrieved articles by examining titles, abstracts and full texts, and then determined whether the article could be included or excluded. The detailed search strategy is shown in [Figure 1](#jcm-09-00326-f001){ref-type="fig"}.

2.2. Eligibility Criteria and Data Extraction {#sec2dot2-jcm-09-00326}
---------------------------------------------

We included meta-analyses and systematic reviews of both RCTs and observational studies (cohort or case-control studies) on the relationship between statin use and cancer mortality or survival. However, we could not find any meta-analysis of RCTs on this association and therefore, only observational studies were included and analyzed. Any mortality or survival outcomes were included and five outcomes (all-cause mortality, cancer-specific mortality, recurrence-free survival, progression-free survival, and disease-free survival) were found in the included meta-analyses on the associations between statin use and cancer mortality or survival. Narrative review articles, in vitro or animal studies and genetic association meta-analyses were excluded in our study. Meta-analyses with insufficient data were also excluded. If there are several meta-analysis articles on the same topic and outcome, we included all the meta-analyses to see whether there are any discrepancies among them.

We obtained the original data from eligible meta-analyses, and extracted and summarized information on the first author, year of publication, the type of cancer, the type of outcome (all-cause mortality, cancer-specific mortality, recurrence-free survival, progression-free survival, and disease-free survival), the study design, the number of included studies, the number of case and total participants, and the random effects with 95% CI. In addition, we extracted the raw datasets of each individual study for the further re-analysis of meta-analysis.

2.3. Statistical Analysis {#sec2dot3-jcm-09-00326}
-------------------------

We firstly reanalyzed each meta-analysis result for the relationship between statin use and cancer mortality or survival. We found that most published meta-analyses presented only the results of random effects and therefore, we performed not only random-effects meta-analysis but also fixed-effect meta-analysis. In addition, if there were overlapping meta-analyses on the same topic, we pooled all the datasets of individual studies from eligible meta-analyses according to the type of cancer or study design and performed re-meta-analysis after eliminating the overlapping individual studies and including missing individual studies. We presented the summary effect size, 95% CI and *p*-value with both random- and fixed-effects. All re-analyses in this study were performed using Comprehensive Meta-Analysis software ver.3.3.070 (Borenstein, Englewood, NJ, USA).

For each meta-analysis, we re-analyzed the individual studies and estimated the summary effects and 95% CI using both fixed and inverse variance random- and fixed-effects methods \[[@B15-jcm-09-00326]\]. We also calculated and presented the 95% prediction intervals (PIs), which address the dispersion of effects in 95% of cases the true effect in a new study will fall within the PIs and further account for between-study heterogeneity \[[@B16-jcm-09-00326]\], whereas CI reflect the accuracy of the mean.

Heterogeneity across the individual studies was assessed using I^2^ metric of inconsistency and the *p*-value of the Cochrane Q test \[[@B17-jcm-09-00326]\]. Publication bias was evaluated by using Egger's regression test \[[@B18-jcm-09-00326]\]. Small study effects were used to detect publication and report bias \[[@B19-jcm-09-00326],[@B20-jcm-09-00326]\]. If Egger's regression test was significant (*p*-value \< 0.10) in random-effects meta-analyses, we judged that the meta-analysis has small-study effects.

2.4. The Criteria to Determine the Level of Evidence {#sec2dot4-jcm-09-00326}
----------------------------------------------------

We determined the level of evidence for each reanalyzed meta-analysis or pooled meta-analysis to strengthen the associations between statin use and cancer mortality or survival. The criteria to determine the level of evidence were classified according to the statistical significance by random and fixed-effects *p*-value, 95% PI, a small-study effect, a between-study heterogeneity and concordance between the result of the largest study among each meta-analysis and that of meta-analysis \[[@B13-jcm-09-00326],[@B21-jcm-09-00326]\]. The level of evidence for the association was determined as follows:

### 2.4.1. Convincing Evidence {#sec2dot4dot1-jcm-09-00326}

There was a strong statistical significance in fixed-effects and random-effects meta-analyses at *p*-value \< 0.001, 95% PI excluded null, there was no large between-study heterogeneity and no small study effects. There was a concordance between the result of the largest study and that of meta-analysis

### 2.4.2. Suggestive Evidence {#sec2dot4dot2-jcm-09-00326}

The significance threshold was crossed for the random summary effects (*p* \< 0.05), but 95% PI included the null and there was not large between-study heterogeneity and there were no small study effects.

### 2.4.3. Weak (Probable) Evidence {#sec2dot4dot3-jcm-09-00326}

The significance threshold was crossed for the random summary effects (*p* \< 0.05), but 95% PI included the null, there was large between-study heterogeneity or small study effects.

### 2.4.4. Nonsignificant Associations {#sec2dot4dot4-jcm-09-00326}

The significance threshold was not crossed for the random summary effects (*p* \> 0.05). However, if the heterogeneity was large, we rechecked the results whether it may be due to differences in the direction of the effect or it can be due to differences in the size of the association although all studies may show increased risk. In the latter case, we re-determined the level of evidence again \[[@B13-jcm-09-00326],[@B21-jcm-09-00326]\].

3. Results {#sec3-jcm-09-00326}
==========

3.1. Search Strategy for the Literature and Included Studies for Reanalysis {#sec3dot1-jcm-09-00326}
---------------------------------------------------------------------------

A total of 335 meta-analyses were retrieved from our PubMed database search. 136 duplicate articles were initially excluded, and an additional 35 articles were screened by title. Another 102 articles were excluded after assessing the abstract, and 46 articles were finally excluded after full-text screening and finally, 16 eligible meta-analyses reporting various kinds of cancer mortality or survival in 11 cancers were finally selected for re-analysis ([Figure 1](#jcm-09-00326-f001){ref-type="fig"}) \[[@B22-jcm-09-00326],[@B23-jcm-09-00326],[@B24-jcm-09-00326],[@B25-jcm-09-00326],[@B26-jcm-09-00326],[@B27-jcm-09-00326],[@B28-jcm-09-00326],[@B29-jcm-09-00326],[@B30-jcm-09-00326],[@B31-jcm-09-00326],[@B32-jcm-09-00326],[@B33-jcm-09-00326],[@B34-jcm-09-00326],[@B35-jcm-09-00326],[@B36-jcm-09-00326],[@B37-jcm-09-00326]\]. Overall, all-cause mortality was reported as outcomes in 11 cancer types, cancer-specific mortality in 8 cancer types, recurrence-free survival in 5 cancer types, progression-free survival in 4 cancer types and disease-free survival in one cancer type ([Table 1](#jcm-09-00326-t001){ref-type="table"}, [Table 2](#jcm-09-00326-t002){ref-type="table"}, [Table 3](#jcm-09-00326-t003){ref-type="table"} and [Table 4](#jcm-09-00326-t004){ref-type="table"}).

3.2. The Effect of Statin on All-Cause Mortality in 11 Cancers {#sec3dot2-jcm-09-00326}
--------------------------------------------------------------

The results of each meta-analysis on the effect of statin on all-cause mortality in various cancer types are summarized in [Table 1](#jcm-09-00326-t001){ref-type="table"} and the results of meta-analyses in which all the individual datasets are pooled are summarized in [Table 4](#jcm-09-00326-t004){ref-type="table"}.

There were no associations between statin use and all-cause mortality in three cancer types (bladder, endometrial and urothelial tract cancer). In breast cancer, three meta-analyses which included any statin use (all weak evidence due to high heterogeneity) and one with pre-diagnostic statin use (suggestive evidence) showed the beneficial effect of statin on all-cause mortality, while there was no significant association between post-diagnostic statin use and all-cause mortality in one meta-analysis. When the individual datasets were all pooled (*n* = 20), the evidence for the effect of statin use in preventing all-cause mortality in breast cancer was suggestive despite a high heterogeneity because it was due to differences in the effect size of the association.

In colorectal cancer, nine of the 10 meta-analyses showed the beneficial effect of statin on all-cause mortality, while only one older meta-analysis showed no significant association between post-diagnostic statin use and all-cause mortality. When the individual datasets were all pooled (*n* = 24), the evidence for the effect of statin use in preventing all-cause mortality in colorectal cancer was suggestive despite a high heterogeneity, because it was due to differences in the effect size of the association.

In endocrine-related gynecological cancer, there was only one meta-analysis (*n* = 9) which showed a beneficial effect of statin on all-cause mortality with suggestive evidence.

In kidney cancer, there were two meta-analyses that showed a beneficial effect of statin on all-cause mortality with one suggestive and the other weak evidence. When the individual datasets were all pooled (*n* = 7), the evidence for the effect of statin use in preventing all-cause mortality in kidney cancer was weak due to small study effects and high heterogeneity.

In ovarian cancer, there were three meta-analyses that showed a beneficial effect of statin on all-cause mortality with one convincing, the other suggestive and another not estimable. When the individual datasets were all pooled (*n* = 7), the evidence for the effect of statin use in preventing all-cause mortality in ovarian cancer was suggestive.

In pancreatic cancer, there was only one meta-analysis (*n* = 6) which showed a beneficial effect of statin on all-cause mortality with weak evidence due to small study effects and high heterogeneity.

In prostate cancer, five of the six meta-analyses showed the beneficial effect of statin on all-cause mortality (two suggestive, two weak and one not estimable), while only one older meta-analysis showed no significant association between post-diagnostic statin use and all-cause mortality. When the individual datasets were all pooled (*n* = 21), the evidence for the effect of statin use in preventing all-cause mortality in prostate cancer was weak due to small study effects and high heterogeneity.

In urothelial tract cancer, there was only one meta-analysis (*n* = 5) which showed a beneficial effect of statin on all-cause mortality with weak evidence due to high heterogeneity.

3.3. The Effect of Statin on Cancer-Specific Mortality in 8 Cancers {#sec3dot3-jcm-09-00326}
-------------------------------------------------------------------

The results of each meta-analysis on the effect of statin on cancer-specific mortality in various cancer types are summarized in [Table 2](#jcm-09-00326-t002){ref-type="table"} and the results of meta-analyses in which all the individual datasets are pooled are summarized in [Table 4](#jcm-09-00326-t004){ref-type="table"}.

There was only one meta-analysis for each in three cancer types (bladder, endocrine-related gynecological cancer, and urothelial tract cancer) and no associations were found between statin use and cancer-specific mortality in each cancer type.

In breast cancer, four of the five meta-analyses showed the beneficial effect of statin on cancer-specific mortality (one suggestive, two weak and one not estimable, but at least suggestive), while only one meta-analysis showed no significant association. When the individual datasets were all pooled (*n* = 28), the evidence for the effect of statin use in preventing cancer-specific mortality in breast cancer was weak due to small study effects and high heterogeneity.

In colorectal cancer, eight of the nine meta-analyses showed the beneficial effect of statin on cancer-specific mortality, while only one older meta-analysis showed no significant association between post-diagnostic statin use and cancer-specific mortality. When the individual datasets were all pooled (*n* = 13), the evidence for the effect of statin use in preventing cancer-specific mortality in colorectal cancer was convincing.

In kidney cancer, there were two meta-analyses that showed a beneficial effect of statin on cancer-specific mortality with one weak and the other not significant in older meta-analysis. When the individual datasets were all pooled (*n* = 6), the evidence for the effect of statin use in preventing cancer-specific mortality in kidney cancer was weak due to high heterogeneity.

In ovarian cancer, there was only one meta-analysis (*n* = 3) which showed a beneficial effect of statin on cancer-specific mortality with weak evidence due to the presence of small study effect.

In prostate cancer, all six of the meta-analyses showed the beneficial effect of statin on cancer-specific mortality (five suggestive and one weak). When the individual datasets were all pooled (*n* = 15), the evidence for the effect of statin use in preventing cancer-specific mortality in prostate cancer was weak due to small study effects and high heterogeneity.

3.4. The Effect of Statin on Recurrence-Free Survival, Progression-Free Survival, and Disease-Free Survival {#sec3dot4-jcm-09-00326}
-----------------------------------------------------------------------------------------------------------

The results of each meta-analysis on the effect of statin on recurrence-free survival, progression-free survival or disease-free survival in various cancer types are summarized in [Table 3](#jcm-09-00326-t003){ref-type="table"} and the pooled results of meta-analyses in recurrence-free survival for kidney cancer are summarized in [Table 4](#jcm-09-00326-t004){ref-type="table"}.

Recurrence-free survival was measured as outcome for the preventive effect of statin in five cancers (bladder, breast, colorectal, kidney and prostate cancer) and no associations were found between statin use and recurrence-free survival in each cancer type in four cancers (bladder, colorectal, kidney and prostate cancer) and there was only one meta-analysis (*n* = 10) which showed a beneficial effect of statin on recurrence-free survival in breast cancer with a suggestive evidence.

Progression-free survival was measured as an outcome for the preventive effect of statin in four cancers (bladder, endocrine-related gynecological cancer, kidney, and prostate cancer) and no associations were found in these cancers.

Disease-free survival was measured as an outcome for the preventive effect of statin in one cancer (colorectal cancer) and no association was found.

4. Discussion {#sec4-jcm-09-00326}
=============

The purpose of this umbrella review of previous meta-analysis and re-analysis of meta-analyses, including all the individual studies was to highlight the potential effects of statin use on cancer mortality or survival. Our team recently examined the association between statin use and cancer incidence, and we found out that there were substantial weak or not significant associations \[[@B13-jcm-09-00326]\]. We further analyzed the data from 16 meta-analyses to evaluate the use of statins and cancer mortality or survival. With only using random-effects *p*-value and effect size with 95% confidence interval (CI) \[[@B38-jcm-09-00326]\], which is a conventional interpretation of current meta-analysis, 14 of 29 associations of cancer mortality or survival showed a statistically significant preventive effect of statin on these outcomes. Among these outcomes, the use of statin significantly decreased the cancer-specific mortality of colorectal cancer supported with a convincing level of evidence. These studies of colorectal cancer on cancer-specific mortality were performed with four meta-analyses with 13 individual studies including a total of 118,996 patients. The main findings with the determined level of evidence were summarized in [Table 5](#jcm-09-00326-t005){ref-type="table"}.

This outcome can be fortified with the preclinical studies of the anticancer effects of adjuvant statin on colorectal cancer \[[@B39-jcm-09-00326]\]. Several mechanisms responsible for anticancer effect on colorectal cancer were inducing apoptosis by down-regulating of anti-apoptotic proteins \[[@B40-jcm-09-00326]\], inhibition of cellular proliferation \[[@B41-jcm-09-00326]\], or inhibition of angiogenesis \[[@B42-jcm-09-00326]\]. Recent studies present that statin inhibits the formation of mevalonate from HMG-CoA, it subsequently inhibits the Ras/Rho prenylation and downstream reactions, expected to overcome the resistance of anti-epidermal growth factor receptor (EGFR) therapy in patients with K-RAS mutation \[[@B43-jcm-09-00326]\]. These beneficial effects of statin on cancer, especially on colorectal cancer, may largely overlapping and can be applied both in the field of cancer prevention and adjuvant cancer therapy.

However, besides the case of colorectal cancer, statin's effect on other types of cancer mortality was supported by a weak or non-significant level of evidence. This can be addressed with possible explanations. First, there was a relatively limited number of studies. Colorectal and breast cancer show a high rate of incidence and mortality worldwide, which leads to a large number of RCTs and observational studies \[[@B44-jcm-09-00326]\]. However, underpowered-studies supported by the small number of studies have limitations to be validated \[[@B45-jcm-09-00326]\]. Due to this reason, further updated meta-analyses should include a large number of individual studies. Also, some cancers innately have poor prognosis or can be detected in a more progressed stage. Cancers such as bladder or pancreatic cancer have a relatively low survival rate in the general population, which may attenuate the effect of statin's benefit.

Among pooled meta-analyses of all-cause mortality of patients with 11 types of cancer, eight of them showed a negative association and four of them had a suggestive level of evidence ([Table 4](#jcm-09-00326-t004){ref-type="table"}). Above all, statin showed a significantly conspicuous effect on all-cause mortality of breast and colorectal cancer patients, supported by a sufficient number of meta-analyses with suggestive or convincing level. Besides, in case of breast cancer, the disease-specific mortality (in this case, breast cancer-specific mortality) showed a negative association with the use of statin, supported by the lower magnitude of effect size and weaker level of evidence. All-cause mortality is a widely adopted result variable of many trials and observational studies because it can present any unexpected lethal outcomes of trials, such as non-cardiovascular outcomes in patients with hyperlipidemia \[[@B46-jcm-09-00326]\]. However, this should be carefully interpreted since most of the statin users have risk factors of cardiovascular diseases or higher rate of cardiovascular death, use of statin can act as confounding factors of the outcome measures.

Most of the results observed the survival rate of cancer (recurrence-free survival, progression-free survival, and disease-free survival) were shown to have non-significant results, except for the results of breast cancer recurrence-free survival. Since studies of these kinds of outcome measures have not widely performed, the sample sizes of individual meta-analyses are limited, which may lead to false-positive estimates. In case of breast cancer recurrence-free survival, it only includes one meta-analysis \[[@B25-jcm-09-00326]\], but with an adequate number of individual studies and sample sizes. To robust the statistical significance, further study should be conducted.

Meta-analysis is an important research design for appraising evidence and guiding medical practice and health policy by combining data from many studies and umbrella review (reviews of previously published systematic reviews or meta-analyses) emerged as an important method of evidence synthesis because it can provide a wider picture compared with a meta-analysis which is limited to one treatment comparison or even one outcome \[[@B47-jcm-09-00326]\]. Recently, however, mass production of flawed meta-analysis also has been a problem in the medical field \[[@B48-jcm-09-00326]\]. Meta-analysis has its own several limitations such as heterogeneity or publication bias. Also, overlapping meta-analyses on the same topic have been an important issue \[[@B49-jcm-09-00326],[@B50-jcm-09-00326]\], because they often show conflicting results among them and our umbrella review also showed that there were many overlapped meta-analyses with discordant results. The most updated meta-analysis should include all the previous individual studies, but some previous studies are frequently missing in the last meta-analysis despite extensive search strategy due to not reviewing the previous meta-analysis on the same topic, which can lead to misleading results. There are several ways to overcome this problem, and therefore, we performed re-analysis by pooling all the individual studies datasets in addition to analysis of each meta-analysis.

Due to these several problems, the results of meta-analysis should be interpreted with caution and recent umbrella reviews suggest the use of several criteria for determining level of evidence such as the degree of *p*-value, the statistical significance in both random and fixed effect models, between-study heterogeneity, small study effect, and 95% PI, which is more strict than the *p*-value alone \[[@B20-jcm-09-00326],[@B21-jcm-09-00326],[@B51-jcm-09-00326]\]. The strength of evidence reinforces the results from the meta-analyses and assists to choose the best evidence for the decision.

Our study has several limitations: (1) we only included the re-analyzable meta-analyses for re-analysis, (2) potential confounding factors differed across the individual studies (3) individual observational studies themselves can have biases, (4) each meta-analysis might include erroneous individual studies, (5) some statistics such as 95% PI and Egger's tests cannot be done if there were small number of individual studies, (6) the criteria we used may not be definitive criteria for assessing the strength of evidence, (7) the dose-effect of statin was beyond the scope of our analysis, (8) and the subgroup analyses of the effects such as adjuvant therapy or underlying patients' conditions were also beyond our scope and were not performed due to lack of studies for the analysis. Future studies should be performed considering limitations of individual meta-analyses and potential biases, and also should consider the dose-dependent effect of statin.

5. Conclusions {#sec5-jcm-09-00326}
==============

Our umbrella review extensively re-analyzed the meta-analyses on the associations between statin use and cancer mortality or survival. 14 of 29 studies on statin-cancer mortality were significant. Especially, the use of statin was significantly associated with a reduction of cancer-specific mortality of colorectal cancer supported by a convincing level of evidence, which can be interpreted that it has a noteworthy association. Although there have been extensive epidemiologic or meta-analysis studies on the associations of statin use with cancer mortality or survival and report many strong claims of significance for the associations, only a minor portion of these associations have convincing or suggestive associations without biases. Our findings would give a clue to clinicians and researchers and help understand the true associations.

The supplementary material is available online at <https://www.mdpi.com/2077-0383/9/2/326/s1>.
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jcm-09-00326-t001_Table 1

###### 

Summary of each individual meta-analysis on associations of the use of statin and all-cause mortality in various cancers.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Type/Author, Year                        Study Design   No of Study   No of Total Participants   Random Effects\   Random Effects\   Fixed Effects\   Largest Effect §   Egger   I^2^ (*P*) †     *P*\       *P*\      95% PI\        Small Study Effect   Same Direction   Evidence
                                                                                                   (Reported)\       (Re-Analyzed)\    (Re-Analyzed)\                                               (Random)   (Fixed)   (Random)                                             
                                                                                                   (ES, 95%CI)       (ES, 95%CI)       (ES, 95%CI)                                                                                                                            
  ---------------------------------------- -------------- ------------- -------------------------- ----------------- ----------------- ---------------- ------------------ ------- ---------------- ---------- --------- -------------- -------------------- ---------------- -----------------
  Bladder cancer                                                                                                                                                                                                                                                              

  Luo 2015                                 Obs            1             1117                       1.14\             1.14\             1.14\            1.14\              \-      \-               0.286      0.286     NA             \-                   No               Non-significant
                                                                                                   (0.89--1.44)      (0.89--1.44)      (0.89--1.44)     (0.89--1.44)                                                                                                          

  Breast cancer                                                                                                                                                                                                                                                               

  Mei 2017                                 Cohort         7             24,255                     0.65\             0.65\             0.72\            0.78\              0.541   92.7 (\<0.001)   0.042      \<0.001   0.15--2.76     No                   Yes              Weak
                                                                                                   (0.43--0.99)      (0.43--0.98)      (0.67--0.77)     (0.72--0.84)                                                                                                          

  Liu 2017                                 Cohort         8             68,373                     0.72\             0.72\             0.74\            0.46\              0.702   87.4 (\<0.001)   0.002      \<0.001   0.36--1.44     No                   Yes              Weak
                                                                                                   (0.58--0.89)      (0.58--0.89)      (0.69--0.78)     (0.38--0.55)                                                                                                          

  Manthravadi 2016                         Cohort         8             40,756                     0.66\             0.66\             0.64\            0.39\              0.864   89.0 (\<0.001)   0.043      \<0.001   0.18--2.40     No                   Yes              Weak
                                                                                                   (0.44--0.99)      (0.44--0.99)      (0.57--0.70)     (0.33--0.46)                                                                                                          

  Zhong 2015 (post-diagnostic)             Obs            6             51,265                     0.75\             0.75\             0.72\            0.47\              0.816   77.8 (\<0.001)   0.079      \<0.001   0.27--2.09     No                   No               Non-significant
                                                                                                   (0.55--1.02)      (0.55--1.03)      (0.64--0.80)     (0.38--0.59)                                                                                                          

  Zhong 2015 (pre-diagnostic)              Obs            3             49,116                     0.73\             0.73\             0.76\            0.60\              0.501   33.3 (0.269)     \<0.001    \<0.001   0.18--2.95     No                   Yes              Suggestive
                                                                                                   (0.62--0.86)      (0.63--0.86)      (0.69--0.83)     (0.45--0.81)                                                                                                          

  Colorectal cancer                                                                                                                                                                                                                                                           

  Mei 2017                                 Cohort         9             44,476                     0.76\             0.76\             0.75\            0.72\              0.793   67.3 (0.002)     \<0.001    \<0.001   0.54--1.07     No                   Yes              Suggestive \*
                                                                                                   (0.68--0.86)      (0.68--0.86)      (0.72--0.80)     (0.67--0.78)                                                                                                          

  Gray 2016 (post-diagnostic)              Obs            11            21,030                     0.84\             0.85\             0.84\            0.90\              0.760   69.0 (\<0.001)   0.029      \<0.001   0.53--1.34     No                   No               Weak
                                                                                                   (0.73--0.98)      (0.73--0.98)      (0.79--0.90)     (0.80--1.01)                                                                                                          

  Gray 2016 (pre-diagnostic)               Obs            6             44,026                     0.85\             0.85\             0.84\            0.85\              0.720   76.0 (\<0.001)   0.011      \<0.001   0.59--1.24     No                   Yes              Suggestive \*
                                                                                                   (0.76--0.96)      (0.76--0.96)      (0.80--0.88)     (0.79--0.92)                                                                                                          

  Ling 2015 (post-diagnostic)              Cohort         5             10,038                     0.93\             0.93\             0.81\            0.75\              0.443   69.4 (0.011)     0.639      \<0.001   0.33--2.59     No                   No               Non-significant
                                                                                                   (0.68--1.27)      (0.68--1.27)      (0.73--0.90)     (0.66--0.84)                                                                                                          

  Ling 2015 (pre-diagnostic)               Cohort         4             12,396                     0.73\             0.73\             0.74\            0.81\              0.251   19.9 (0.291)     \<0.001    \<0.001   0.45--1.19     No                   Yes              Suggestive
                                                                                                   (0.61--0.88)      (0.62--0.86)      (0.66--0.84)     (0.68--0.96)                                                                                                          

  Cai 2015 (post & pre-diagnostic)         Obs            4             11,786                     0.76\             0.79\             0.79\            0.71\              0.587   0.0 (0.447)      0.013      0.013     0.52--1.18     No                   Yes              Suggestive
                                                                                                   (0.61--0.95)      (0.65--0.95)      (0.65--0.95)     (0.54--0.94)                                                                                                          

  Cai 2015 (post-diagnostic)               Obs            4             15,862                     0.76\             0.76\             0.76\            0.75\              0.723   0.0 (0.393)      \<0.001    \<0.001   0.60--0.96     No                   Yes              Convincing
                                                                                                   (0.68--0.85)      (0.68--0.85)      (0.68--0.85)     (0.66--0.84)                                                                                                          

  Cai 2015 (pre-diagnostic)                Obs            2             10,553                     0.70\             0.70\             0.70\            0.71\              \-      0.0 (0.795)      0.007      0.007     NA             \-                   Yes              \-
                                                                                                   (0.54--0.91)      (0.54--0.91)      (0.54--0.91)     (0.54--0.94)                                                                                                          

  Zhong 2015 (post-diagnostic)             Obs            6             12,441                     0.96\             0.97\             0.86\            0.75\              0.295   65.9 (0.004)     0.792      0.003     0.45--2.09     No                   No               Weak
                                                                                                   (0.76--1.22)      (0.75--1.24)      (0.77--0.95)     (0.66--0.85)                                                                                                          

  Zhong 2015 (pre-diagnostic)              Obs            3             18,733                     0.77\             0.78\             0.79\            0.82\              0.353   31.4 (0.300)     \<0.001    \<0.001   0.27--2.25     No                   Yes              Suggestive
                                                                                                   (0.66--0.89)      (0.69--0.88)      (0.72--0.87)     (0.74--0.91)                                                                                                          

  Endocrine-Related Gynecological Cancer                                                                                                                                                                                                                                      

  Xie 2017                                 Obs            9             5449                       \-                0.70\             0.71\            0.66\              0.250   33.3 (0.151)     \<0.001    \<0.001   0.47--1.04     No                   Yes              Suggestive
                                                                                                                     (0.58--0.83)      (0.63--0.80)     (0.55--0.80)                                                                                                          

  Endometrial Cancer                                                                                                                                                                                                                                                          

  Xie 2017                                 Obs            4             3460                       \-                0.80\             0.84\            0.92\              0.046   0.0 (0.680)      0.083      0.058     0.34--1.89     Yes                  Yes              Non-significant
                                                                                                                     (0.62--1.03)      (0.69--1.01)     (0.70--1.20)                                                                                                          

  Zhong 2015 (post-diagnostic)             Obs            3             3261                       0.89\             0.86\             0.89\            0.92\              0.156   0.0 (0.203)      0.309      0.255     0.05--13.49    No                   Yes              Non-significant
                                                                                                   (0.72--1.09)      (0.64--1.15)      (0.72--1.09)     (0.70--1.20)                                                                                                          

  Kidney Cancer                                                                                                                                                                                                                                                               

  Nayan 2017                               Overall        7             11,491                     0.74\             0.74\             0.78\            0.80\              0.057   51.8 (0.052)     0.001      \<0.001   0.47--1.17     Yes                  Yes              Weak
                                                                                                   (0.63--0.88)      (0.63--0.88)      (0.71--0.87)     (0.66--0.97)                                                                                                          

  Luo 2015                                 Obs            3             5881                       0.81\             0.81\             0.82\            0.84\              0.378   26.0 (0.260)     0.015      0.005     0.19--3.47     No                   No               Suggestive
                                                                                                   (0.68--0.96)      (0.69--0.96)      (0.72--0.94)     (0.69--1.00)                                                                                                          

  Lymphoma                                                                                                                                                                                                                                                                    

  Zhong 2015 (post-diagnostic)             Obs            3             782                        1.15\             1.15\             1.15\            1.23\              0.195   0.0 (0.602)      0.362      0.362     0.16--8.24     No                   Yes              Non-significant
                                                                                                   (0.85--1.55)      (0.85--1.55)      (0.85--1.55)     (0.88--1.71)                                                                                                          

  Ovarian Cancer                                                                                                                                                                                                                                                              

  Li 2018                                  Obs            7             16,389                     0.74\             0.74\             0.79\            0.81\              0.061   55.0 (0.038)     \<0.001    \<0.001   0.49--1.11     No                   Yes              Suggestive
                                                                                                   (0.63--0.87)      (0.63--0.87)      (0.73--0.86)     (0.72--0.90)                                                                                                          

  Xie 2017                                 Obs            5             1989                       \-                0.63\             0.63\            0.66\              0.200   0.0 (0.680)      \<0.001    \<0.001   0.48--0.82     No                   Yes              Convincing
                                                                                                                     (0.54--0.74)      (0.54--0.74)     (0.55--0.80)                                                                                                          

  Zhong 2015\                              Obs            2             276                        0.39\             0.39\             0.39\            0.24\              \-      0.0 (0.395)      0.002      0.002     NA             \-                   Yes              \-
  (post-diagnostic)                                                                                (0.22--0.71)      (0.22--0.71)      (0.22--0.71)     (0.07--0.87)                                                                                                          

  Pancreatic Cancer                                                                                                                                                                                                                                                           

  Jian-Yu 2018                             Overall        6             12,057                     0.75\             0.81\             0.92\            0.94\              0.008   81.1 (\<0.001)   0.009      0.001     0.52--1.26     Yes                  No               Weak
                                                                                                   (0.59--0.90)      (0.69--0.95)      (0.87--0.97)     (0.89--1.01)                                                                                                          

  Prostate Cancer                                                                                                                                                                                                                                                             

  Mei 2017                                 Cohort         10            73,716                     0.72\             0.72\             0.89\            0.79\              0.044   95.0 (\<0.001)   \<0.001    \<0.001   0.46--1.12     Yes                  Yes              Weak
                                                                                                   (0.63--0.81)      (0.63--0.81)      (0.87--0.91)     (0.76--0.82)                                                                                                          

  Meng 2016 (post-diagnostic)              Obs            7             58,838                     0.84\             0.77\             0.80\            0.79\              0.376   72.0 (0.002)     \<0.001    \<0.001   0.54--1.09     No                   Yes              Suggestive \*
                                                                                                   (0.71--0.99)      (0.68--0.86)      (0.76--0.83)     (0.75--0.83)                                                                                                          

  Meng 2016 (pre-diagnostic)               Obs            2             1337                       0.56\             0.56\             0.56\            0.57\              \-      0.0 (0.770)      0.004      0.004     NA             \-                   Yes              \-
                                                                                                   (0.38--0.85)      (0.38--0.83)      (0.38--0.83)     (0.38--0.85)                                                                                                          

  Raval 2016                               Cohort         6             31,539                     0.76\             0.76\             0.80\            0.86\              0.503   71.0 (0.004)     0.004      \<0.001   0.44--1.29     No                   Yes              Weak
                                                                                                   (0.63--0.90)      (0.63--0.91)      (−0.75--0.86)    (0.78--0.95)                                                                                                          

  Luo 2015                                 Obs            5             22,439                     0.82\             0.83\             0.85\            0.86\              0.461   46.0 (0.110)     0.022      \<0.001   0.52--1.31     No                   Yes              Suggestive
                                                                                                   (0.70--0.97)      (0.70--0.97)      (0.78--0.93)     (0.78--0.95)                                                                                                          

  Zhong 2015\                              Obs            3             18,814                     0.59\             0.59\             0.82\            0.86\              0.228   84.1 (0.001)     0.053      \<0.001   0.00--406.64   No                   No               Non-significant
  (post-diagnostic)                                                                                (0.35--0.99)      (0.34--1.01)      (0.75--0.90)     (0.78--0.95)                                                                                                          

  Urothelial Tract Cancer                                                                                                                                                                                                                                                     

  Zhong 2015\                              Obs            5             9488                       0.87\             0.87\             0.87\            0.89\              0.917   52.8 (0.070)     0.049      0.001     0.56--1.34     No                   No               Weak
  (post-diagnostic)                                                                                (0.75--1.00)      (0.75--1.00)      (0.79--0.95)     (0.71--1.12)                                                                                                          
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ES, Effect size; CI, Confidence interval; PI, Prediction interval; Obs, Observational study. § Risk ratio (95% Confidence interval) of the largest study in each meta-analysis. † I^2^ metric of inconsistency (95% confidence interval of I^2^) and *P*-value of the Cochran Q test for evaluation of heterogeneity. \* Convincing or suggestive level of evidence due to the greater number of studies that decrease risk.

jcm-09-00326-t002_Table 2

###### 

Summary of each individual meta-analysis on associations of the use of statin and cancer-specific mortality in various cancers.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Type/Author, Year                Study Design   No of Study   No of Total Participants   Random Effects\   Random Effects\   Fixed Effects\   Largest Effect §   Egger   I^2^ (*P*) †     *P*\       *P*\      95% PI\         Small Study Effect   Same Direction   Evidence
                                                                                           (Reported)\       (Re-Analyzed)\    (Re-Analyzed)\                                               (Random)   (Fixed)   (Random)                                              
                                                                                           (ES, 95%CI)       (ES, 95%CI)       (ES, 95%CI)                                                                                                                             
  -------------------------------- -------------- ------------- -------------------------- ----------------- ----------------- ---------------- ------------------ ------- ---------------- ---------- --------- --------------- -------------------- ---------------- -----------------
  Bladder cancer                                                                                                                                                                                                                                                       

  Luo 2015                         Obs            2             2619                       1.06\             1.06\             1.06\            1.04\              \-      0.0 (0.590)      0.559      0.559     NA              \-                   Yes              Non-significant
                                                                                           (0.87--1.29)      (0.87--1.29)      (0.87--1.29)     (0.84--1.28)                                                                                                           

  Breast cancer                                                                                                                                                                                                                                                        

  Liu 2017                         Cohort         8             196,120                    0.73\             0.73\             0.73\            0.85\              0.997   85.6 (\<0.001)   0.007      \<0.001   0.34--1.58      No                   Yes              Weak
                                                                                           (0.59--0.92)      (0.58--0.92)      (0.67--0.78)     (0.74--0.98)                                                                                                           

  Manthravadi 2016                 Cohort         6             46,970                     0.30\             0.69\             0.62\            0.35\              0.591   86.0 (\<0.001)   0.091      \<0.001   0.16--2.92      No                   No               Non-significant
                                                                                           (0.46--1.06)      (0.45--1.06)      (0.54--0.71)     (0.28--0.45)                                                                                                           

  Mansourian 2016                  Obs            13            99,610                     0.85\             0.85\             0.85\            0.83\              0.465   8.6 (0.360)      \<0.001    \<0.001   NA              No                   Yes              \-
                                                                                           (0.83--0.87)      (0.82--0.88)      (0.83--0.87)     (0.80--0.86)                                                                                                           

  Zhong 2015 (post-diagnostic)     Obs            3             49,116                     0.60\             0.60\             0.60\            0.47\              0.995   84.1 (\<0.001)   0.018      \<0.001   0.00--106.05    No                   Yes              Weak
                                                                                           (0.41--0.88)      (0.39--0.92)      (0.52--0.69)     (0.39--0.57)                                                                                                           

  Zhong 2015 (pre-diagnostic)      Obs            4             88,235                     0.73\             0.77\             0.77\            0.60\              0.002   21.5 (0.428)     \<0.001    \<0.001   0.59--1.01      Yes                  No               Suggestive
                                                                                           (0.61--0.89)      (0.68--0.87)      (0.68--0.87)     (0.35--1.01)                                                                                                           

  Colorectal cancer                                                                                                                                                                                                                                                    

  Gray 2016 (post-diagnostic)      Obs            4             19,152                     0.84\             0.84\             0.82\            0.90\              0.887   67.0 (0.030)     0.118      \<0.001   0.36--2.00      No                   Yes              Non-significant
                                                                                           (0.68--1.04)      (0.68--1.04)      (0.75--0.91)     (0.77--1.05)                                                                                                           

  Gray 2016 (pre-diagnostic)       Obs            6             86,622                     0.82\             0.82\             0.82\            0.81\              0.152   0.0 (0.570)      \<0.001    \<0.001   NA              No                   Yes              \-
                                                                                           (0.79--0.86)      (0.79--0.86)      (0.79--0.86)     (0.75--0.88)                                                                                                           

  Ling 2015 (post-diagnostic)      Cohort         3             8667                       0.70\             0.70\             0.70\            0.71\              0.219   0.0 (0.535)      \<0.001    \<0.001   0.26--1.87      No                   Yes              Suggestive
                                                                                           (0.60--0.81)      (0.60--0.82)      (0.60--0.82)     (0.61--0.84)                                                                                                           

  Ling 2015 (pre-diagnostic)       Cohort         6             74,042                     0.80\             0.80\             0.80\            0.79\              0.231   10.8 (0.347)     \<0.001    \<0.001   0.74--0.88      No                   Yes              Convincing
                                                                                           (0.77--0.84)      (0.77--0.84)      (0.77--0.84)     (0.74--0.85)                                                                                                           

  Cai 2015 (pre&post-diagnostic)   Obs            6             69,949                     0.80\             0.80\             0.80\            0.79\              0.172   19.3 (0.288)     \<0.001    \<0.001   0.71--0.90      No                   Yes              Convincing
                                                                                           (0.75--0.85)      (0.75--0.85)      (0.77--0.85)     (0.74--0.85)                                                                                                           

  Cai 2015 (post-diagnostic)       Obs            3             15,023                     0.70\             0.70\             0.70\            0.71\              0.219   0.0 (0.535)      \<0.001    \<0.001   0.26--1.87      No                   Yes              Suggestive
                                                                                           (0.60--0.81)      (0.60--0.82)      (0.60--0.82)     (0.61--0.84)                                                                                                           

  Cai 2015 (pre-diagnostic)        Obs            5             69,375                     0.80\             0.80\             0.81\            0.79\              0.298   28.3 (0.233)     \<0.001    \<0.001   0.67--0.95      No                   Yes              Convincing
                                                                                           (0.74--0.86)      (0.74--0.86)      (0.77--0.85)     (0.74--0.85)                                                                                                           

  Zhong 2015 (post-diagnostic)     Obs            4             11,070                     0.79\             0.79\             0.77\            0.71\              0.959   60.5 (0.058)     0.141      \<0.001   0.24--2.65      No                   No               Weak
                                                                                           (0.58--1.08)      (0.58--1.08)      (0.67--0.88)     (0.61--0.83)                                                                                                           

  Zhong 2015 (pre-diagnostic)      Obs            3             25,081                     0.82\             0.82\             0.83\            0.77\              0.414   36.2 (0.239)     \<0.001    \<0.001   0.31--2.19      No                   Yes              Suggestive
                                                                                           (0.73--0.91)      (0.74--0.90)      (0.78--0.89)     (0.68--0.88)                                                                                                           

  Endocrine gynecological cancer                                                                                                                                                                                                                                       

  Xie 2017                         Obs            4             1079                       \-                0.75\             0.72\            0.74\              0.357   35.1 (0.202)     0.057      0.004     0.27--2.09      No                   Yes              Non-significant
                                                                                                             (0.55--1.01)      (0.58--0.90)     (0.54--1.02)                                                                                                           

  Kidney cancer                                                                                                                                                                                                                                                        

  Nayan 2017                       Overall        6             10,337                     0.67\             0.67\             0.81\            0.85\              0.120   67.0 (0.010)     0.022      0.003     0.25--1.82      No                   No               Weak
                                                                                           (0.47--0.94)      (0.48--0.94)      (0.71--0.93)     (0.72--1.01)                                                                                                           

  Luo 2015                         Obs            2             3273                       0.71\             0.72\             0.84\            1.02\              --      82.0 (0.020)     0.389      0.222     NA              \-                   Yes              Non-significant
                                                                                           (0.35--1.50)      (0.35--1.51)      (0.64--1.11)     (0.74--1.39)                                                                                                           

  Ovarian cancer                                                                                                                                                                                                                                                       

  Li 2018                          Obs            3             27,690                     0.87\             0.87\             0.87\            0.93\              0.577   0.0 (0.411)      0.002      0.002     0.50--1.54      No                   No               Weak
                                                                                           (0.80--0.95)      (0.80--0.95)      (0.80--0.95)     (0.81--1.08)                                                                                                           

  Prostate cancer                                                                                                                                                                                                                                                      

  Meng 2016 (post-diagnostic)      Obs            4             57,058                     0.64\             0.64\             0.73\            0.74\              0.254   82.0 (\<0.001)   \<0.001    \<0.001   0.27--1.55      No                   Yes              Suggestive \*
                                                                                           (0.52--0.79)      (0.52--0.79)      (0.69--0.77)     (0.70--0.79)                                                                                                           

  Meng 2016 (pre-diagnostic)       Obs            6             35,684                     0.53\             0.54\             0.78\            0.81\              0.019   77.0 (\<0.001)   0.001      \<0.001   0.18--1.64      Yes                  Yes              Weak
                                                                                           (0.29--0.98)      (0.37--0.78)      (0.72--0.84)     (0.75--0.88)                                                                                                           

  Raval 2016                       Cohort         5             21,306                     0.76\             0.76\             0.76\            0.76\              0.593   30.0 (0.150)     0.001      \<0.001   0.49--1.17      No                   Yes              Suggestive
                                                                                           (0.64--0.89)      (0.64--0.89)      (0.69--0.84)     (0.66--0.88)                                                                                                           

  Luo 2015                         Obs            7             28,897                     0.70\             0.70\             0.74\            0.76\              0.011   43.0 (0.100)     \<0.001    \<0.001   0.48--1.04      Yes                  Yes              Suggestive
                                                                                           (0.59--0.83)      (0.60--0.83)      (0.68--0.82)     (0.66--0.88)                                                                                                           

  Zhong 2015 (post-diagnostic)     Obs            3             19,322                     0.77\             0.77\             0.77\            0.76\              0.973   0.0 (0.970)      \<0.001    \<0.001   0.38--1.54      No                   Yes              Suggestive
                                                                                           (0.70--0.85)      (0.70--0.85)      (0.70--0.85)     (0.66--0.88)                                                                                                           

  Zhong 2015 (pre-diagnostic)      Obs            3             5460                       0.44\             0.44\             0.72\            0.78\              0.148   86.3 (0.001)     0.029      \<0.001   Not estimable   No                   Yes              Suggestive \*
                                                                                           (0.20--0.93)      (0.21--0.92)      (0.62--0.82)     (0.67--0.90)                                                                                                           

  Urothelial tract cancer                                                                                                                                                                                                                                              

  Zhong 2015 (post-diagnostic)     Obs            4             6880                       0.86\             0.87\             0.87\            0.86\              0.901   61.8 (0.073)     0.307      0.070     0.30--2.53      No                   Yes              Non-significant
                                                                                           (0.65--1.16)      (0.66--1.14)      (0.76--1.01)     (0.72--1.03)                                                                                                           
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ES, Effect size; CI, Confidence interval; PI, Prediction interval; Obs, Observational study. § Risk ratio (95% Confidence interval) of the largest study in each meta-analysis. † I^2^ metric of inconsistency (95% confidence interval of I^2^) and *P*-value of the Cochran Q test for evaluation of heterogeneity. \* Convincing or suggestive level of evidence due to the greater number of studies that decrease risk.

jcm-09-00326-t003_Table 3

###### 

Summary of each individual meta-analysis on associations of the use of statin and recurrence-free survival, progression-free survival and disease-free survival in various cancers.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Type/Author, Year                Study Design   No of Study   No of Total Participants   Random Effects\   Random Effects\   Fixed Effects\   Largest Effect §   Egger   I^2^ (*P*) †     *P*\       *P*\      95% PI\       Small Study Effect   Same Direction   Evidence
                                                                                           (Reported)\       (Re-Analyzed)\    (Re-Analyzed)\                                               (Random)   (Fixed)   (Random)                                            
                                                                                           (ES, 95%CI)       (ES, 95%CI)       (ES, 95%CI)                                                                                                                           
  -------------------------------- -------------- ------------- -------------------------- ----------------- ----------------- ---------------- ------------------ ------- ---------------- ---------- --------- ------------- -------------------- ---------------- -----------------
  **Recurrence-free survival**                                                                                                                                                                                                                                       

  Bladder cancer                                                                                                                                                                                                                                                     

  Luo 2015                         Obs            3             3571                       1.05\             1.06\             1.06\            1.04\              0.844   0.0 (0.950)      0.375      0.375     0.47--2.36    No                   Yes              Non-significant
                                                                                           (0.94--1.18)      (0.94--1.19)      (0.94--1.19)     (0.96--1.24)                                                                                                         

  Breast cancer                                                                                                                                                                                                                                                      

  Manthravadi 2016                 Cohort         10            32,373                     0.64\             0.64\             0.69\            0.80\              0.093   44.0 (0.070)     \<0.001    \<0.001   0.38--1.09    Yes                  Yes              Suggestive
                                                                                           (0.53--0.79)      (0.52--0.79)      (0.60--0.79)     (0.64--1.00)                                                                                                         

  Colorectal cancer                                                                                                                                                                                                                                                  

  Cai 2015                         Obs            2             1233                       0.98\             0.98\             1.12\            1.28\              --      26.1 (0.345)     0.975      0.730     NA            \-                   Yes              Non-significant
                                                                                           (0.36--2.70)      (0.36--2.70)      (0.58--2.15)     (0.64--2.54)                                                                                                         

  Kidney cancer                                                                                                                                                                                                                                                      

  Nayan 2017                       Overall        4             2197                       0.97\             0.97\             1.00\            1.09\              0.364   55.2 (0.082)     0.524      0.899     0.70--1.36    No                   Yes              Non-significant
                                                                                           (0.89--1.06)      (0.89--1.06)      (0.99--1.01)     (0.65--1.81)                                                                                                         

  Luo 2015                         Obs            3             5080                       0.91\             0.91\             1.00\            1.22\              0.783   72.0 (0.030)     0.736      0.991     0.47--2.36    No                   Yes              Non-significant
                                                                                           (0.54--1.55)      (0.54--1.55)      (0.81--1.23)     (0.95--1.57)                                                                                                         

  Prostate cancer                                                                                                                                                                                                                                                    

  Park 2013                        Cohort         13            21,185                     0.90\             0.90\             0.92\            0.99\              0.649   69.6 (\<0.001)   0.252      0.057     0.48--1.67    No                   Yes              Non-significant
                                                                                           (0.74--1.08)      (0.74--1.08)      (0.84--1.00)     (0.83--1.18)                                                                                                         

  **Progression-free survival**                                                                                                                                                                                                                                      

  Bladder cancer                                                                                                                                                                                                                                                     

  Luo 2015                         Obs            2             2069                       0.87\             0.87\             0.87\            0.77\              0.461   0.0 (0.370)      0.320      0.320     NA            No                   Yes              Non-significant
                                                                                           (0.65--1.15)      (0.65--1.15)      (0.65--1.15)     (0.52--1.13)                                                                                                         

  Endocrine gynecological cancer                                                                                                                                                                                                                                     

  Xie 2017                         Obs            3             421                        \-                0.69\             0.68\            0.65\              0.439   33.6 (0.222)     0.066      0.018     0.02--27.87   No                   Yes              Non-significant
                                                                                                             (0.46--1.02)      (0.49--0.93)     (0.39--1.07)                                                                                                         

  Kidney cancer                                                                                                                                                                                                                                                      

  Nayan 2017                       Overall        2             4965                       0.92\             0.92\             1.00\            0.67\              --      86.2 (0.007)     0.772      0.996     NA            \-                   No               Non-significant
                                                                                           (0.51--1.65)      (0.51--1.65)      (0.82--1.23)     (0.47--0.96)                                                                                                         

  Prostate cancer                                                                                                                                                                                                                                                    

  Luo 2015                         Obs            5             6032                       0.84\             0.84\             0.87\            1.10\              0.607   52 (0.080)       0.260      0.148     0.34--2.10    No                   Yes              Non-significant
                                                                                           (0.62--1.14)      (0.62--1.14)      (0.71--1.05)     (0.78--1.56)                                                                                                         

  **Disease-free survival**                                                                                                                                                                                                                                          

  Colorectal cancer                                                                                                                                                                                                                                                  

  Cai 2015                         Obs            2             1233                       1.13\             1.13\             1.13\            1.07\              \-      0.0 (0.691)      0.514      0.514     NA            \-                   Yes              Non-significant
                                                                                           (0.78--1.62)      (0.78--1.62)      (0.78--1.62)     (0.68--1.67)                                                                                                         
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ES, Effect size; CI, Confidence interval; PI, Prediction interval; Obs, Observational study; § Risk ratio (95% Confidence interval) of the largest study in each meta-analysis. † I^2^ metric of inconsistency (95% confidence interval of I^2^) and *P*-value of the Cochran Q test for evaluation of heterogeneity.
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###### 

Summary of the meta-analysis results by pooling all the datasets on associations of statin and the mortality or survival.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cancer Type                              No of Studies   No of Total Participants   Random Effects\     *P*\       Fixed Effects\      *P*\      Largest Effect §\   D/N/I     Egger   I^2^ (*P*) †     95% PI\       95% PI\       Concordant Direction   Evidence
                                                                                      (RR, 95%CI)         (Random)   (RR, 95%CI)         (Fixed)   (RR, 95%CI)                                            (Random)      (Fixed)                              
  ---------------------------------------- --------------- -------------------------- ------------------- ---------- ------------------- --------- ------------------- --------- ------- ---------------- ------------- ------------- ---------------------- -----------------
  **All-cause mortality**                                                                                                                                                                                                                                    

  Bladder cancer                           1               1117                       1.14 (0.89--1.44)   0.286      1.14 (0.89--1.44)   0.286     1.14 (0.89--1.44)   0/1/0     \-      \-               NA            NA            No                     Non-significant

  Breast cancer                            20              160,806                    0.65 (0.55--0.77)   \<0.001    0.66 (0.62--0.70)   \<0.001   0.54 (0.44--0.67)   12/0/8    0.787   85.2 (\<0.001)   0.33--1.29    0.34--1.28    Yes                    Suggestive \*

  Colorectal cancer                        24              85,231                     0.81 (0.75--0.88)   \<0.001    0.82 (0.80--0.86)   \<0.001   0.82 (0.74--0.90)   15/8/1    0.444   68.1 (\<0.001)   0.60--1.10    0.61--1.11    Yes                    Suggestive \*

  Endocrine-related gynecological cancer   9               5449                       0.70 (0.58--0.83)   \<0.001    0.71 (0.63--0.80)   \<0.001   0.66 (0.55--0.80)   4/5/0     0.250   33.3 (0.151)     0.47--1.04    0.49--1.03    Yes                    Suggestive

  Endometrial cancer                       4               3460                       0.80 (0.62--1.03)   0.083      0.84 (0.69--1.01)   0.058     0.92 (0.70--1.20)   1/3/0     0.046   36.1 (0.196)     0.34--1.89    0.38--1.82    Yes                    Non-significant

  Kidney cancer                            7               11,491                     0.74 (0.63--0.88)   0.001      0.78 (0.71--0.87)   \<0.001   0.80 (0.66--0.98)   4/3/0     0.057   51.8 (0.053)     0.47--1.17    0.51--1.20    Yes                    Weak

  Lymphoma                                 3               782                        1.15 (0.85--1.55)   0.362      1.15 (0.85--1.55)   0.362     1.23 (0.88--1.71)   0/3/0     0.195   0.0 (0.602)      0.16--8.24    0.16--8.24    Yes                    Non-significant

  Ovarian cancer                           7               16,307                     0.74 (0.63--0.87)   \<0.001    0.79 (0.73--0.86)   \<0.001   0.81 (0.72--0.90)   4/3/0     0.067   0.0 (0.411)      0.49--1.12    0.55--1.15    Yes                    Suggestive

  Pancreatic cancer                        6               12,057                     0.81 (0.69--0.95)   0.009      0.92 (0.87--0.97)   0.001     0.94 (0.89--1.01)   3/3/0     0.008   81.1 (\<0.001)   0.52--1.26    0.62--1.36    No                     Weak

  Prostate cancer                          21              95,128                     0.73 (0.67--0.81)   \<0.001    0.89 (0.88--0.91)   \<0.001   0.79 (0.75--0.83)   15/6/0    0.002   89.9 (\<0.001)   0.50--1.08    0.61--1.30    No                     Weak

  Urothelial tract cancer                  5               9488                       0.87 (0.75--1.00)   0.049      0.87 (0.79--0.95)   0.001     0.89 (0.71--1.12)   2/3/0     0.917   52.8 (0.070)     0.56--1.34    0.58--1.29    No                     Weak

  **Cancer-specific mortality**                                                                                                                                                                                                                              

  Bladder cancer                           2               2619                       1.06 (0.87--1.29)   0.559      1.06 (0.87--1.29)   0.559     1.04 (0.84--1.28)   0/2/0     \-      0.0 (0.590)      NA            NA            Yes                    Non-significant

  Breast cancer                            28              424,694                    0.71 (0.65--0.78)   \<0.001    0.82 (0.80--0.84)   \<0.001   0.83 (0.80--0.86)   12/16/0   0.044   84.0 (\<0.001)   0.50--1.02    0.58--1.16    Yes                    Weak

  Colorectal cancer                        13              118,996                    0.81 (0.78--0.85)   \<0.001    0.82 (0.79--0.85)   \<0.001   0.77 (0.69--0.87)   8/5/0     0.282   26.2 (0.180)     0.72--0.92    0.74--0.90    Yes                    Convincing

  Endocrine-related gynecological cancer   4               1079                       0.75 (0.55--1.01)   0.057      0.72 (0.58--0.90)   0.004     0.74 (0.54--1.02)   1/3/0     0.357   35.1 (0.202)     0.27--2.09    0.29--1.82    Yes                    Non-significant

  Kidney cancer                            6               10,337                     0.67 (0.48--0.94)   0.022      0.81 (0.71--0.93)   0.003     0.85 (0.72--1.01)   3/3/0     0.120   66.6 (0.011)     0.25--1.82    0.33--1.98    No                     Weak

  Ovarian cancer                           3               27,690                     0.87 (0.80--0.95)   0.002      0.87 (0.80--0.95)   0.002     0.93 (0.81--1.08)   1/2/0     0.577   0.0 (0.411)      0.50--1.54    0.50--1.54    No                     Weak

  Prostate cancer                          15              101,378                    0.66 (0.58--0.74)   \<0.001    0.74 (0.71--0.78)   \<0.001   0.74 (0.70--0.79)   11/4/0    0.010   68.3 (\<0.001)   0.47--0.93    0.54--1.02    Yes                    Weak

  Urothelial tract cancer                  4               6880                       0.87 (0.66--1.14)   0.307      0.87 (0.76--1.01)   0.070     0.86 (0.72--1.03)   1/3/0     0.901   61.8 (0.073)     0.30--2.53    0.34--2.22    Yes                    Non-significant

  **Recurrence-free survival**                                                                                                                                                                                                                               

  Bladder cancer                           3               3571                       1.06 (0.94--1.19)   0.375      1.06 (0.94--1.19)   0.375     1.04 (0.96--1.24)   0/3/0     0.844   0.0 (0.950)      0.47--2.36    0.47--2.36    Yes                    Non-significant

  Breast cancer                            10              32,373                     0.64 (0.52--0.79)   \<0.001    0.69 (0.60--0.79)   \<0.001   0.80 (0.64--1.00)   6/4/0     0.093   44.0 (0.070)     0.38--1.09    0.42--1.14    Yes                    Weak

  Colorectal cancer                        2               1233                       0.98 (0.36--2.70)   0.975      1.12 (0.58--2.15)   0.730     1.28 (0.64--2.54)   0/2/0     \-      26.1 (0.345)     NA            NA            Yes                    Non-significant

  Kidney cancer                            4               2197                       0.97 (0.89--1.06)   0.524      1.00 (0.99--1.01)   0.899     1.09 (0.65--1.81)   1/3/0     0.364   56.8 (0.074)     0.70--1.36    0.36--1.31    Yes                    Non-significant

  Prostate cancer                          13              21,185                     0.90 (0.74--1.08)   0.252      0.92 (0.84--1.00)   0.057     0.99 (0.83--1.18)   5/7/1     0.649   69.6 (\<0.001)   0.48--1.67    0.50--1.66    Yes                    Non-significant

  **Progression-free survival**                                                                                                                                                                                                                              

  Bladder cancer                           2               2069                       0.87 (0.65--1.15)   0.320      0.87 (0.65--1.15)   0.320     0.77 (0.52--1.13)   0/2/0     0.461   0.0 (0.370)      NA            NA            Yes                    Non-significant

  Endocrine-related gynecological cancer   3               421                        0.69 (0.46--1.02)   0.066      0.68 (0.49--0.93)   0.018     0.65 (0.39--1.07)   1/2/0     0.439   33.6 (0.222)     0.02--27.87   0.02--19.47   Yes                    Non-significant

  Kidney cancer                            2               4965                       0.92 (0.51--1.65)   0.772      1.00 (0.82--1.23)   0.996     0.67 (0.47--0.96)   1/1/0     \-      86.2 (0.007)     NA            NA            No                     Non-significant

  Prostate cancer                          5               6032                       0.84 (0.62--1.14)   0.260      0.87 (0.71--1.05)   0.148     1.10 (0.78--1.56)   2/3/0     0.607   52 (0.080)       0.34--2.10    0.38--2.00    Yes                    Non-significant

  **Disease-free survival**                                                                                                                                                                                                                                  

  Colorectal cancer                        2               1,233                      1.13 (0.78--1.62)   0.514      1.13 (0.78--1.62)   0.514     1.07 (0.68--1.67)   0/2/0     \-      0.0 (0.691)      NA            NA            Yes                    Non-significant
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

D/N/I, Decreasing risk/No difference/Increasing risk; RR, Risk ratio; CI, Confidence interval; PI, Prediction. § Risk ratio (95% Confidence interval) of the largest study in each meta-analysis. † I^2^ metric of inconsistency (95% confidence interval of I^2^) and *P*-value of the Cochran Q test for evaluation of heterogeneity. \* Suggestive or convincing level of evidence due to the greater number of studies that decrease risk in which a high heterogeneity is due to differences in the effect size of the association.
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###### 

Evidence of association between statin use and mortality or survival outcomes.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Evidence Category   All-Cause Mortality \*                                       Cancer-Specific Mortality                 Recurrence Free Survival           Progression-Free Survival                 Disease-Free Survival
  ------------------- ------------------------------------------------------------ ----------------------------------------- ---------------------------------- ----------------------------------------- -----------------------
  Convincing          \-                                                           Colorectal cancer (0.82; 0.79--0.85)      \-                                 \-                                        \-

  Suggestive          Breast cancer (0.65; 0.55--0.77)\                            \-                                        \-                                 \-                                        \-
                      Colorectal cancer (0.82; 0.75--0.88)\                                                                                                                                               
                      Endocrine-related gynecological cancer (0.71; 0.58--0.83)\                                                                                                                          
                      Ovarian cancer (0.74; 0.63--0.87)                                                                                                                                                   

  Weak                Kidney cancer (0.73; 0.71--0.87)\                            Breast cancer (0.71; 0.65--0.78)\         Breast cancer (0.64; 0.52--0.79)   \-                                        \-
                      Pancreatic cancer (0.81; 0.69--0.95)\                        Kidney cancer (0.67; 0.48--0.94)\                                                                                      
                      Prostate cancer (0.89; 0.88--0.91)\                          Ovarian cancer (0.87; 0.80--0.95)\                                                                                     
                      Urothelial tract cancer (0.87; 0.75--1.00)                   Prostate cancer (0.66; 0.58--0.74)                                                                                     

  Non-significant     Bladder cancer\                                              Bladder cancer\                           Bladder cancer\                    Bladder cancer\                           Colorectal cancer
                      Endometrial cancer\                                          Endocrine-related gynecological cancer\   Colorectal cancer\                 Endocrine-related gynecological cancer\   
                      Lymphoma                                                     Urothelial tract cancer                   Kidney cancer\                     Kidney cancer\                            
                                                                                                                             Prostate cancer                    Prostate cancer                           
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* Results with statistically significant association (convincing, suggestive and weak) were presented with its random summary effects and 95% confidence interval.
